Aromasin and Hypercoagulation - a phase IV clinical study of FDA data

Summary:

Hypercoagulation is reported as a side effect among people who take Aromasin (exemestane), especially for people who are female, 60+ old, also take Arimidex, and have Metastases to bone.

The phase IV clinical study analyzes which people have Hypercoagulation when taking Aromasin. It is created by eHealthMe based on reports of 12,620 people who have side effects when taking Aromasin from the FDA, and is updated regularly.

What is Aromasin?

Aromasin has active ingredients of exemestane. It is often used in breast cancer. eHealthMe is studying from 12,863 Aromasin users. Check the latest studies of Aromasin.

What is Hypercoagulation?

Hypercoagulation (increased tendency for clotting of the blood) is found to be associated with 419 drugs and 535 conditions by eHealthMe. Check the latest studies of Hypercoagulation.

On Jan, 26, 2026

12,620 people reported to have side effects when taking Aromasin.
Among them, 28 people (0.22%) have Hypercoagulation.

Among these 28 people:

What is the gender of people who have Hypercoagulation when taking Aromasin? *

female: 96.43 %
male: 3.57 %

What is the age of people who have Hypercoagulation when taking Aromasin? *

What are other drugs people take besides Aromasin? *

What are other side effects people have besides Hypercoagulation? *

Joint Pain: 27 people, 96.43%
Fatigue (feeling of tiredness): 25 people, 89.29%
Weight Decreased: 24 people, 85.71%
Back Pain: 24 people, 85.71%
Metastases To Bone (cancer spreads to bone): 24 people, 85.71%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 24 people, 85.71%
Osteosclerosis (an elevation in bone density): 24 people, 85.71%
Osteomyelitis (infection of bone): 23 people, 82.14%
Tenderness (pain or discomfort when an affected area is touched): 23 people, 82.14%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 22 people, 78.57%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 22 people, 78.57%
Osteoporosis (bones weak and more likely to break): 3 people, 10.71%
Bone Loss: 3 people, 10.71%
Renal Disorder (kidney disease): 2 people, 7.14%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 3.57%
Quit Smoking: 1 person, 3.57%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 3.57%
Gastritis (inflammation of stomach): 1 person, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Aromasin and have Hypercoagulation?

- Check whether Hypercoagulation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aromasin:

Aromasin (12,863 reports)

Browse all side effects of Aromasin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypercoagulation:

Hypercoagulation (419 drugs)

Browse all the conditions that are associated with Hypercoagulation:

Hypercoagulation (535 conditions)

Drugs similar to Aromasin and Hypercoagulation :

How the study uses the data?

The study uses data from the FDA. It is based on exemestane (the active ingredients of Aromasin) and Aromasin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.